Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA, United States.
University Center of Gastrointestinal and Liver Diseases-Clarunis, University of Basel, Basel, Switzerland.
Front Endocrinol (Lausanne). 2021 Apr 20;12:666565. doi: 10.3389/fendo.2021.666565. eCollection 2021.
Stem cell-based therapies to reconstitute organ function hold great promise for future clinical applications to a variety of diseases. Hypothyroidism resulting from congenital lack of functional thyrocytes, surgical tissue removal, or gland ablation, represents a particularly attractive endocrine disease target that may be conceivably cured by transplantation of long-lived functional thyroid progenitors or mature follicular epithelial cells, provided a source of autologous cells can be generated and a variety of technical and biological challenges can be surmounted. Here we review the emerging literature indicating that thyroid follicular epithelial cells can now be engineered from the pluripotent stem cells (PSCs) of mice, normal humans, or patients with congenital hypothyroidism. We review the embryonic development of the thyroid gland and explain how emerging discoveries in developmental biology have been utilized as a roadmap for driving PSCs, which resemble cells of the early embryo, into mature functional thyroid follicles . Finally, we discuss the bioengineering, biological, and clinical hurdles that now need to be addressed if the goals of life-long cure of hypothyroidism through cell- and/or gene-based therapies are to be attained.
基于干细胞的疗法有望为未来的临床应用于各种疾病而重新构建器官功能。由于先天性缺乏功能性甲状腺细胞、手术组织切除或腺体消融而导致的甲状腺功能减退症,是一种特别有吸引力的内分泌疾病靶点,通过移植具有长期功能的甲状腺祖细胞或成熟滤泡上皮细胞,也许可以治愈该疾病,前提是可以生成自体细胞并且可以克服各种技术和生物学挑战。在这里,我们回顾了新兴文献,这些文献表明,现在可以从多能干细胞(PSCs)的小鼠、正常人类或先天性甲状腺功能减退症患者中设计出甲状腺滤泡上皮细胞。我们回顾了甲状腺的胚胎发育,并解释了发育生物学中的新兴发现如何被用作指导多能干细胞的路线图,这些多能干细胞类似于早期胚胎的细胞,并将其转化为成熟的功能性甲状腺滤泡。最后,如果要通过细胞和/或基因疗法实现终生治愈甲状腺功能减退症的目标,我们讨论了生物工程、生物学和临床障碍,这些障碍现在需要解决。